Citigroup Inc. set a $100.00 price objective on AveXis, Inc. (NASDAQ:AVXS) in a research note issued to investors on Thursday. The brokerage currently has a buy rating on the stock.

Several other brokerages also recently weighed in on AVXS. BMO Capital Markets reissued an outperform rating and issued a $95.00 price target (up previously from $85.00) on shares of AveXis in a report on Friday, March 17th. Jefferies Group LLC raised their price target on AveXis from $79.00 to $92.00 and gave the stock a buy rating in a report on Friday, March 17th. Goldman Sachs Group, Inc. (The) raised their price target on AveXis from $91.00 to $108.00 and gave the stock a buy rating in a report on Friday, March 17th. Finally, Chardan Capital reissued a buy rating and issued a $100.00 price target on shares of AveXis in a report on Friday, March 17th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. AveXis presently has an average rating of Buy and a consensus target price of $87.86.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, May 11th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by $0.13. During the same quarter in the prior year, the company earned ($1.24) earnings per share.

COPYRIGHT VIOLATION WARNING: “Citigroup Inc. Analysts Give AveXis, Inc. (AVXS) a $100.00 Price Target” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/citigroup-inc-analysts-give-avexis-inc-avxs-a-100-00-price-target/1380715.html.

In other news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $81.39, for a total value of $144,874.20. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at $144,874.20. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 5,341 shares of company stock valued at $406,682.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new position in shares of AveXis during the first quarter valued at about $117,000. Quantitative Systematic Strategies LLC purchased a new position in shares of AveXis during the first quarter valued at about $201,000. Virginia Retirement Systems ET AL purchased a new position in shares of AveXis during the first quarter valued at about $205,000. Opus Point Partners Management LLC purchased a new position in shares of AveXis during the fourth quarter valued at about $239,000. Finally, Nationwide Fund Advisors boosted its position in shares of AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock valued at $262,000 after buying an additional 284 shares during the last quarter. Hedge funds and other institutional investors own 90.47% of the company’s stock.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.